Product
GD2 T cells
1 clinical trial
2 indications
Indication
OsteosarcomaIndication
NeuroblastomaClinical trial
Vaccination to Enhance the Anti-Tumor Activity of GD2 Chimeric Antigen Receptor-Expressing, VZV-Specific T Cells in Subjects With Advanced Sarcomas and Neuroblastoma (VEGAS)Status: Active (not recruiting), Estimated PCD: 2019-10-31